PCSA Processa Pharmaceuticals, Inc.

Nasdaq processapharmaceuticals.com


$ 0.26 $ -0.02 (-7.16 %)    

Friday, 21-Nov-2025 15:55:01 EST
QQQ $ 589.60 $ 4.40 (0.75 %)
DIA $ 462.45 $ 5.05 (1.1 %)
SPY $ 658.47 $ 6.50 (1 %)
TLT $ 89.50 $ 0.27 (0.3 %)
GLD $ 373.70 $ -0.58 (-0.15 %)
$ 0.253
$ 0.28
$ 0.26 x 500
$ 0.27 x 1,000
$ 0.26 - $ 0.28
$ 0.15 - $ 1.50
1,023,741
na
14.33M
$ 0.82
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 processa-pharmas-abstract-adaptive-phase-23-study-for-pcs499-499-in-patients-with-focal-segmental-glomerulosclerosis-fsgs-accepted-for-presentation-at-asn-kidney-week-2025

Processa Pharmaceuticals, Inc. (NASDAQ:PCSA), a clinical-stage biopharmaceutical company developing Next Generation Cancer (NGC...

 why-processa-pharmaceuticals-stock-rose-almost-38-overnight

Processa Pharmaceuticals shares jumped 37.5% after hours following a strong regular session, despite facing significant losses ...

 hc-wainwright--co-maintains-buy-on-processa-pharmaceuticals-lowers-price-target-to-1

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCSA) with a Buy and lowers th...

 processa-pharma-q2-eps-025-misses-020-estimate

Processa Pharma (NASDAQ:PCSA) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate of $(0...

 processa-pharmaceuticals-signs-binding-term-sheet-granting-intact-therapeutics-an-exclusive-option-to-license-pcs12852-strengthens-balance-sheet-with-7m-capital-infusion

Signed binding term sheet granting Intact Therapeutics an exclusive option to license PCS12852Continue enrolling patients in Ph...

 hc-wainwright--co-maintains-buy-on-processa-pharmaceuticals-lowers-price-target-to-2

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Processa Pharmaceuticals (NASDAQ:PCSA) with a Buy and lowers th...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION